The University of Michigan Comprehensive Cancer Center and Tempus, a health technology company dedicated to personalizing cancer care, recently partnered to offer the Michigan Oncology Sequencing Center (MI-ONCOSEQ) panel to health care providers and patients in the U.S.
MI-ONCOSEQ technology is specifically designed for people wanting high-quality data and analyses that are needed for personalized treatments. The panel uses high-throughput gene sequencing techniques within a specific clinical setting. This will help to develop new options for cancer patients who do not have a typical standard of care or who have an ineffective standard of care.
Each cancer has a unique genetic and molecular profile made up of countless genes. This requires researchers and doctors to use enormous quantities of data to detect patterns that improve patient outcomes.
Tempus hired world-class data scientists, geneticists, computational biologists and software engineers to create this technology, helping physicians have decision support when their patients don’t respond to traditional cancer treatments.
"A 'one-size-fits-all' approach is not effective in managing cancer,” Dr. Arul Chinnaiyan, developer of the panel and director of the Michigan Center for Translational Pathology, said. “Licensing the MI-ONCOSEQ panel to Tempus, we hope to make it commonplace for patients to have a molecular blueprint of their tumor and for their physicians to have access to innovative clinical research and analytic tools that will provide evidence for their decision making.”
